Compare BBNX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBNX | MYGN |
|---|---|---|
| Founded | 2015 | 1991 |
| Country | United States | United States |
| Employees | 423 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.1M | 444.2M |
| IPO Year | N/A | 1996 |
| Metric | BBNX | MYGN |
|---|---|---|
| Price | $16.49 | $5.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $23.80 | $7.64 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $34.90 | $6.86 |
| Revenue Next Year | $34.63 | $5.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $8.80 | $3.53 |
| 52 Week High | $32.71 | $8.59 |
| Indicator | BBNX | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.40 | 73.10 |
| Support Level | $16.02 | $4.29 |
| Resistance Level | $32.52 | $7.29 |
| Average True Range (ATR) | 1.07 | 0.31 |
| MACD | 0.14 | 0.15 |
| Stochastic Oscillator | 83.89 | 93.27 |
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.